Kvantify Advances Hybrid Quantum-Classical Software for Drug Discovery

Kvantify Advances Hybrid Quantum-Classical Software for Drug Discovery

HPCwire
HPCwireMar 13, 2026

Key Takeaways

  • €7M round fuels hybrid quantum drug discovery software
  • Qrunch platform enables chemists to run quantum‑classical simulations
  • ODAQS project applies reinforcement learning to optimize quantum code
  • Kvantify leverages Denmark’s Gefion supercomputer for quantum simulations
  • FAST‑VQE demonstrated on ~50‑qubit systems, showing scalability

Summary

Kvantify closed a €7 million second‑stage funding round to accelerate its hybrid quantum‑classical software stack for drug discovery, building on a $10.8 million seed round and earlier EU Innovation Council support. The company’s Qrunch platform integrates conventional chemistry methods with proprietary FAST‑VQE and BEAST‑VQE algorithms, allowing researchers to run molecular simulations without deep quantum‑programming expertise. Kvantify also joined the ODAQS project, a university‑led effort that uses reinforcement learning to automate quantum software design, and is exploiting Denmark’s Gefion supercomputer to simulate quantum workloads beyond current hardware limits. Recent demos of FAST‑VQE on near‑50‑qubit devices highlight the scalability of its hybrid approach.

Pulse Analysis

Hybrid quantum‑classical workflows are emerging as the most pragmatic path for applying quantum computing to drug discovery, and Kvantify is positioning itself at the forefront. By marrying conventional computational chemistry with quantum algorithms such as FAST‑VQE and BEAST‑VQE, its Qrunch platform abstracts the complexity of quantum programming, enabling chemists to focus on molecular design. This approach reduces the need for deep quantum expertise and makes it feasible for pharmaceutical labs to experiment with quantum‑accelerated simulations today, even on noisy intermediate‑scale quantum (NISQ) hardware.

The recent €7 million financing round underscores investor confidence in Kvantify’s software‑first strategy. Coupled with a $10.8 million seed round and European Innovation Council backing, the capital will fund further development, scaling, and commercialization of the Qrunch suite. Parallelly, the ODAQS collaboration with Aarhus and Aalborg universities introduces reinforcement‑learning techniques to automatically generate efficient quantum programs, addressing one of the biggest bottlenecks: resource‑intensive quantum circuit optimization. This academic partnership not only accelerates algorithmic innovation but also creates a pipeline of talent and IP that strengthens Kvantify’s market position.

Leveraging Denmark’s national AI supercomputer, Gefion, Kvantify can simulate quantum systems far beyond the capabilities of existing quantum processors. These large‑scale classical simulations allow rapid testing of new algorithms, validation of chemical models, and preparation for future hardware upgrades. As quantum processors scale toward higher qubit counts, the company’s hybrid stack—bolstered by advanced software tooling and robust classical support—will be critical for delivering actionable insights in pharmaceutical research, potentially compressing discovery timelines and reducing development costs.

Kvantify Advances Hybrid Quantum-Classical Software for Drug Discovery

Comments

Want to join the conversation?